Get access to our best features
Get access to our best features
Published 23 days ago

Ozempic and Wegovy could double as kidney disease treatment, study suggests

  • The FLOW study involved 3,533 patients and showed a 24% decrease in kidney disease progression and cardiovascular and kidney death after 3.4 years.
  • Patients treated with semaglutide had slower kidney function decline, 18% lower risk of major cardiovascular events, and 20% lower risk of death compared to those on a placebo.
  • Semaglutide use in type 2 diabetes patients with chronic kidney disease reduces major kidney outcomes and risk of cardiovascular events, as stated by Perkovic.
Insights by Ground AI
Does this summary seem wrong?

0 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 83% of the sources are Center
84% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)